Search the Newsreel

Abcellera Biologics Inc (ABCL) Income Statement

This article presents the quarterly and annual income statements for Abcellera Biologics Inc (ABCL), detailing revenues, operating expenses, and net income figures. It provides a comprehensive breakdown of financial performance over several fiscal periods, alongside frequently asked questions to help investors interpret the data. …

BCE Inc (BCE) Income Statement

This article provides a detailed income statement for BCE Inc. (BCE), covering quarterly and annual financial performance metrics from FY2012Q1 to FY2026Q1. It includes key financial figures such as total revenue, operating expenses, net income, and earnings per share, along with year-over-year percentage changes. …

ABCL|Abcellera Biologics Inc|Price:5.310|Chg%:-0.360

This article provides a detailed company profile of Abcellera Biologics Inc (ABCL), an antibody discovery and development company. It outlines their business scope, financial data, and market performance, including an overview of their internal pipeline programs and key executive information. The report also lists …

Abcellera Biologics Inc (ABCL) Cash Flow

This article provides a detailed cash flow statement for Abcellera Biologics Inc (ABCL), presenting quarterly and annual data for operating, investing, and financing activities. It includes key metrics like operating cash flow, capital expenditures, and free cash flow, along with definitions and FAQs to …

BCE, Inc. $BCE Shares Sold by Public Employees Retirement System of Ohio

The Public Employees Retirement System of Ohio reduced its stake in BCE, Inc. (NYSE:BCE) by 23.1% in the first quarter of 2026, selling 143,813 shares and retaining 478,756 shares valued at approximately $12.0 million. Despite mixed analyst ratings, with TD Securities upgrading to "buy" …

First Trust Advisors LP Reduces Position in BCE, Inc. $BCE

First Trust Advisors LP decreased its stake in BCE, Inc. by 18.7% in the first quarter, selling over 420,000 shares and retaining 1.83 million shares valued at $46.3 million. Despite a recent earnings beat and an 8.2% dividend yield, BCE's stock opened near its …

AbCellera's AI-Driven Pivot: Why Jazz Pharma and ABCL635 Data Signal a New Era for the Biotech

AbCellera Biologics (ABCL) is transforming from an antibody discovery platform to a proprietary drug development company, evidenced by a significant collaboration with Jazz Pharmaceuticals worth up to $876 million and promising interim Phase 1 data for its lead internal program, ABCL635. This strategic pivot …

BCE, Inc. Revenue Breakdown – NYSE:BCE

This article provides a revenue breakdown for BCE, Inc. (NYSE: BCE), highlighting its top-performing segment and geographical contribution. Last year, the company generated $17.82 billion USD, with the Bell Communication and Technology Services segment contributing $15.77 billion USD, and Canada accounting for $17.53 billion …

Bce Inc (BCEN) Q1 2023 Earnings Report - Results, Call & Slides

Bce Inc (BCEN) reported its Q1 2023 earnings, beating analyst expectations with an actual EPS of $10.58 against a consensus of $9.69, and revenue of $75.32 billion versus an expected $74.47 billion. This represents a 3.49% year-over-year revenue growth. The report includes details on …

BCAEF SEC Filings - BCE INC 10-K, 10-Q, 8-K Forms

This page on StockTitan.net provides comprehensive access to SEC filings for BCE Inc. (Ticker: BCAEF), including 10-K annual reports, 10-Q quarterly earnings, and 8-K material event reports. It details the types of documents available, such as foreign issuer reports on Form 6-K and various …

BCE Inc (BCE) Financial Health: Profitability & Balance Sheet Analysis

BCE Inc (BCE) currently has a financial score of 7.58, ranking 19th out of 54 in the Telecommunications Services industry. The company's financial status is weak with average operating efficiency, despite recent quarterly revenue increasing by 5.99% to $4.51 billion and net profit growing …

AbCellera Biologics Market Sentiment

This article provides an overview of AbCellera Biologics (ABCL) market sentiment based on analyst consensus, short interest, options flow, and insider activity. It highlights that analysts have a "Buy" consensus with an average price target of $12, while short interest is rising at 20.6%. …

BCE Inc (BCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for BCE Inc (BCE), detailing its performance across various business segments. The data, updated on April 6, indicates that Services data and Services Wireless are the largest contributors to the company's revenue. Regional revenue data has not yet …

AbCellera Biologics, Inc. Revenue Breakdown – DUS:8QQ

AbCellera Biologics, Inc. (DUS:8QQ) generated €63.97 million in revenue last year, primarily from its Antibody Medicines segment. This represents a significant increase from €27.85 million in the previous year. The majority of the company's revenue, €54.49 million, originated from Canada.

Why Did Canerector Exit BCE Inc. and What Does It Mean for the Telecom Sector

Canerector Inc., a leading North American holding company, has fully divested its CA$190.16 million stake in BCE Inc., Canada's largest telecom provider, signaling a strategic shift away from the telecom sector. The company has aggressively reallocated this capital primarily into the Canadian banking sector, …

Abcellera Biologics Inc (ABCL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Abcellera Biologics Inc (ABCL) based on TradingKey's stock score system, which currently ranks its valuation score at 7.22 out of 386 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -11.83, …

ABCL|Abcellera Biologics Inc|Price:5.665|Chg%:-0.065

Abcellera Biologics Inc. (ABCL) is currently trading at $5.475, experiencing a -3.44% decrease. The company's fundamentals are stable with high growth potential, and its valuation is considered fairly valued within the Biotechnology & Medical Research industry. Analysts predominantly rate ABCL as a Buy, with …

Bank of Nova Scotia Increases Stock Holdings in BCE, Inc. $BCE

Bank of Nova Scotia significantly increased its stake in BCE, Inc., adding over 160,000 shares to reach a total of 17.3 million shares valued at approximately $436.3 million. Despite BCE's stock trading near its 52-week low with a market cap of $19.8 billion and …

BCE Inc. (NYSE: BCE) to convert all Series AJ preferred shares by August 4, 2026

BCE Inc. has announced that all its floating-rate Series AJ Preferred Shares will convert to fixed-rate Series AI Preferred Shares on August 4, 2026, on a one-for-one basis. This widespread conversion is triggered because the number of Series AJ shares tendered for conversion into …

BCE reports results of Series AI and AJ preferred share conversions

MONTRÉAL, July 22, 2026 /CNW/ -- BCE Inc. (TSX: BCE) (NYSE: BCE) today announced that all of its floating-rate Cumulative Redeemable First Preferred Shares, Series AJ ("Series AJ Preferred Shares") will be converted on August 4, 2026, on a one-for-one basis, into fixed-rate Cumulative …

BCE to Automatically Convert Remaining Series AJ Shares Aug. 4

BCE (TSX: BCE, NYSE: BCE) will automatically convert all remaining floating-rate Cumulative Redeemable First Preferred Shares, Series AJ, into fixed-rate Cumulative Redeemable First Preferred Shares, Series AI, on a one-for-one basis effective August 4, 2026. This decision follows conversion elections that resulted in fewer …

Abcellera Biologics, Inc. (8QQ) Q3 2024 Earnings Report - Results, Call & Slides

Abcellera Biologics (8QQ) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -€0.15 against a consensus of -€0.11 and actual revenue of €5.70M compared to an expected €6.73M. The Q3 2024 earnings call was scheduled …

BCE Inc. stock remains steady Tuesday, underperforms market

BCE Inc. (BCE) stock remained unchanged on Tuesday, despite a positive trading session for the broader Canadian market. The S&P/TSX Composite Index rose 1.17%, while BCE Inc. closed 15.7% below its 52-week high, indicating an underperformance compared to the market.

BCE Inc. stock outperforms market despite losses on the day

BCE Inc. shares dropped 0.16% to C$30.57 on Monday, despite the broader Canadian market, as represented by the S&P/TSX Composite Index, falling 0.86%. The company's stock closed 15.7% below its 52-week high of C$36.25, achieved on March 17th.

Does AbCellera’s New Board Appointment Reframe Its Execution Story for Investors in ABCL?

AbCellera Biologics announced the appointment of Lynn Seely, M.D., to its Board of Directors, bringing extensive experience in clinical development and commercialization, particularly in oncology. This appointment is expected to strengthen AbCellera's board-level expertise, aligning with its strategic focus on internal clinical programs and …

BCE (BCE) Q3 2024 earnings summary

BCE reported Q3 2024 earnings with adjusted EBITDA growing 2.1% to a record 45.6% margin, but a net loss of $1,191 million due to $2.1 billion in non-cash media asset impairment charges. Free cash flow increased by 10.3%, while revenue declined 1.8%. The company …

Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11

Cantor Fitzgerald has reiterated an Overweight rating and an $11.00 price target for AbCellera Biologics (NASDAQ:ABCL). The firm anticipates positive Phase 2 data for AbCellera's anti-NK3R antibody ABCL635 in Q3 2026, expecting favorable comparisons to approved inhibitors and a significant potential market opportunity. This …

1 High-Yield Dividend Stock You Can Buy and Hold for a Decade

BCE Inc. (TSX:BCE) is presented as a high-yield dividend stock with a current yield of 5.7%. The article discusses BCE's challenging past, including a significant dividend cut and stock price decrease due to network upgrade investments and rising interest rates. However, it also highlights …

Cantor Fitzgerald reiterates Overweight on AbCellera stock at $11 By Investing.com

Cantor Fitzgerald has reiterated an Overweight rating and an $11 price target on AbCellera Biologics (NASDAQ: ABCL). The firm anticipates positive Phase 2 data for ABCL635, an anti-NK3R antibody for menopausal vasomotor symptoms, expecting favorable comparisons to approved inhibitors and a significant market opportunity. …

BCE Inc Is Maintained at Equal-Weight by Barclays

Barclays has maintained an "Equal-Weight" rating for BCE Inc. The article title provides this specific analyst rating and the source of the information. Most of the provided text consists of boilerplate disclaimers and navigation from the Webull platform.

How Bce Inc. (BCE) Affects Rotational Strategy Timing

This article analyzes BCE Inc. (BCE) using AI models to provide insights for rotational strategy timing, identifying choppy sentiment with no clear price positioning signal but elevated downside risk. It outlines three institutional trading strategies (Position Trading, Momentum Breakout, Risk Hedging) with specific entry, …

Bce Inc (BCE) Q3 2024 Earnings Report - Results, Call & Slides

Bce Inc (BCE) reported its Q3 2024 earnings, missing both EPS and revenue expectations. The company's actual EPS was C$0.75 against a consensus of C$0.77, and actual revenue was C$5.97 billion compared to an expected C$6.04 billion. The report includes details on past and …

JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13

JonesTrading has reiterated its Buy rating for AbCellera Biologics (ABCL.US), maintaining a target price of $13. This indicates continued confidence from the analyst firm in the company's stock performance.

BCE Maintained by Barclays -- Price Target Lowered to $25.00

Barclays has maintained an Equal-Weight rating for BCE Inc. but lowered its price target from $26.00 to $25.00, reflecting a cautious outlook on the telecommunications sector. Despite this, GuruFocus indicates BCE is undervalued, with a GF Value™ of $26.89 against a current price of …

BCE Inc. Is Maintained at Buy by Desjardins Securities

Desjardins Securities has reaffirmed its "Buy" rating for BCE Inc. The financial institution continues to show confidence in the telecommunications company. This indicates a positive outlook on BCE Inc.'s stock performance.

ABCL Stock Jumps As Earnings Beat And Drug Data Fuel Momentum